Virtual trial technology lands in Europe

14 October 2019

US-based digital health company VirTrial has launched an alliance with Pratia, the largest network of clinical research centers in Europe, to bring its virtual trial technology across the Atlantic.

The firm said that all Pratia research centers have now completed VirTrial’s training program, making them the first site network in Europe ready to conduct decentralized clinical trials (DCT) using this approach.

Based in Arizona, VirTrial has a telehealth platform which it hopes will help make clinical trials more efficient, using a combination of video, text, and email to allow drug developers to replace some study visits with virtual visits.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK